Skip links

Digital Twins in Pharma: Challenges & Opportunities

Jump To Section

The concept of Digital Twins is being actively investigated by Pharma companies. This technology has great promise as one of the levers to modernize the pharmaceutical industry.
Digital Twin Pharma industry

The concept of Digital Twins is being actively investigated by Pharma companies. This technology has great promise as one of the levers to modernize the pharmaceutical industry. A recent digital health technology report states that 66% of pharma organizations are planning to invest in digital twins in the upcoming years. According to Markets and Markets research, the digital twin market is expected to reach 73.5 billion by 2027 growing at a CAGR of 60.6% (2022-2027).

growth chart

What is a Digital Twin? 

A digital twin is a virtual representation of a physical asset, process, or system that allows for real-time monitoring, analysis, and optimization. It is created using data from various sources, such as sensors, electronic health records, and imaging technologies, and can be used to simulate the behaviour of the physical counterpart.

How does it apply to the pharmaceutical industry?

In the pharmaceutical industry, a digital twin is a virtual representation of a drug, process, or system that is used to optimize the drug development process. As mentioned in the above statement digital twins can be created using data from various sources, including electronic health records, wearable devices, and imaging technologies. In the pharma industry, digital twins can be used to simulate the behaviour of a drug in the body, allowing researchers to better understand its potential side effects and tailor the dosage and administration accordingly. This can lead to more personalized and effective treatment for patients. This can help identify bottlenecks or potential issues before they occur in the physical process, saving time and resources.

Some of the Key Challenges in the Clinical Trial Process

Recruitment and retention of study participants: It can be challenging to find and enroll enough qualified study participants, and to keep them engaged and compliant with the study protocol, especially for rare diseases or conditions. Recruiting and retaining patients for clinical trials has always been a barrier. Currently, 85% of all clinical trials fail to recruit enough patients, and 80% are delayed due to recruitment problems.

Data collection and management: Compared to traditional trials, decentralised clinical trials generate large amounts of data that must be collected, managed, and analyzed accurately and efficiently. This can be a complex and time-consuming task, particularly when dealing with large amounts of data from multiple sources.

Multiple site management: It can be challenging to design a clinical trial that is scientifically rigorous, ethically sound, and practical to implement. Clinical trials occur in multiple sites thus increasing the number of sites, participants, and vendors leading to complex situations or circumstances.

Regulatory approvalClinical trials must adhere to strict regulatory guidelines to ensure the safety and effectiveness of new drugs and treatments. This can involve navigating complex regulatory processes and complying with various requirements for the conduct of clinical trials.

Ensuring the safety of participants: Clinical trials must follow strict ethical guidelines to ensure the safety and well-being of participants. This can involve obtaining informed consent from participants, protecting their privacy, and minimizing any risks to their health.

Quality control: Ensuring the quality and reliability of data collected during clinical trials is critical to the success of these studies. This can involve implementing strict quality control measures to ensure that data is collected and analyzed accurately and consistently.

Some medtech companies are working with digital twins, but they face several challenges in accessing patient data due to privacy and security concerns, issues related to data ownership, challenges in ensuring data quality and completeness, and the presence of data silos.

What the future looks like

Traditional clinical trials are now moving towards decentralised clinical trials that are conducted remotely or outside of traditional research settings. Digital twins in decentralized clinical trials can simulate the trial environment and assess feasibility. They can simulate drug distribution, data collection, and communication between participants and staff. This helps identify challenges and opportunities related to decentralization and develop strategies for addressing them. Digital twins may provide a useful tool for optimizing trial design and improving efficiency and effectiveness.

Pharma companies can adopt data technologies such as machine learning, analytics, and cloud computing to leverage digital twins more effectively. These technologies can be used to improve the accuracy and reliability of digital twin simulations, and to process and analyze large amounts of data generated by digital twins.

Additionally, pharma companies can use data technologies to integrate digital twins with other systems and processes, such as supply chain management, manufacturing, and regulatory compliance. By adopting these technologies, pharma companies can gain a deeper understanding of their products and processes and use digital twins to optimize their operations and improve their decision-making.

Stay tuned for more on the ways advanced technology and analytics impact clinical trials and their usage which is showing great promise to the pharma industry.

Picture of R Ganesh

R Ganesh

Suggested Reading

Ready to Unlock Your Enterprise's Full Potential?

Michael Woodall

Chief Growth Officer of Financial Services

Michael Woodall, as the Chief Growth Officer of Financial Services at Altimetrik, spearheads the identification of new growth avenues and revenue streams within the financial services sector. With a robust background and extensive expertise, Michael brings invaluable insights to his role.

Previously, Michael served as the Chief of Operations and President of the Trust Company at Putnam Investments, where he orchestrated strategic developments and continuous operational enhancements. Leveraging strategic partnerships and data analytics, he revolutionized capabilities across investments, retail and institutional distribution, and client services. Under his leadership, Putnam received numerous accolades, including the DALBAR Mutual Fund Service Award for over 30 consecutive years.

Michael’s dedication to industry evolution is evident through his involvement with prestigious organizations such as the DTCC Senior Wealth Advisory Board, ICI Operations Committee, and NICSA, where he served as Chairman and now holds the position of Director Emeritus. Widely recognized as an industry luminary, Michael frequently shares his expertise with various divisions of the SEC, solidifying his reputation as a seasoned presenter.

At Altimetrik, Michael plays a pivotal role in driving expansion within financial services, leveraging his expertise and Altimetrik’s Digital Business Methodology to ensure clients navigate their digital journey seamlessly, achieving tangible outcomes and exponential growth.

Beyond his corporate roles, Michael serves as Chair of the Boston Water & Sewer Commission, appointed by the Mayor of Boston, and is actively involved in various philanthropic endeavors, including serving on the board of the nonprofit Inspire Arts & Music.

Michael holds a distinguished business degree from Northeastern University, graduating with distinction as a member of the Sigma Epsilon Rho Honor Society.

Anguraj Kumar Arumugam

Chief Digital Business Officer for the U.S. West region

Anguraj is an accomplished business executive with an extensive leadership experience in the services industry and strong background across digital transformation, engineering services, data and analytics, cloud and consulting.

Prior to joining Altimetrik, Anguraj has served in various positions and roles at Globant, GlobalLogic, Wipro and TechMahindra. Over his 25 years career, he has led many strategic and large-scale digital engineering and transformation programs for some of world’s best-known brands. His clients represent a range of industry sectors including Automotive, Technology and Software Platforms. Anguraj has built and guided all-star teams throughout his tenure, bringing together the best of the techno-functional capabilities to address critical client challenges and deliver value.

Anguraj holds a bachelor’s degree in mechanical engineering from Anna University and a master’s degree in software systems from Birla Institute of Technology, Pilani.

In his spare time, he enjoys long walks, hiking, gardening, and listening to music.

Vikas Krishan

Chief Digital Business Officer and Head of the EMEA region

Vikas (Vik) Krishan serves as the Chief Digital Business Officer and Head of the EMEA region for Altimetrik. He is responsible for leading and growing the company’s presence across new and existing client relationships within the region.

Vik is a seasoned executive and brings over 25 years of global experience in Financial Services, Digital, Management Consulting, Pre- and Post-deal services and large/ strategic transformational programmes, gained in a variety of senior global leadership roles at firms such as Globant, HCL, Wipro, Logica and EDS and started his career within Investment Banking. He has developed significant cross industry experience across a wide variety of verticals, with a particular focus on working with and advising the C-Suite of Financial Institutions, Private Equity firms and FinTech’s on strategy and growth, operational excellence, performance improvement and digital adoption.

He has served as the engagement lead on multiple global transactions to enable the orchestration of business, technology, and operational change to drive growth and client retention.

Vik, who is based in London, serves as a trustee for the Burma Star Memorial Fund, is a keen photographer and an avid sportsman.

Megan Farrell Herrmanns

Chief Digital Officer, US Central

Megan is a senior business executive with a passion for empowering customers to reach their highest potential. She has depth and breadth of experience working across large enterprise and commercial customers, and across technical and industry domains. With a track record of driving measurable results, she develops trusted relationships with client executives to drive organizational growth, unlock business value, and internalize the use of digital business as a differentiator.

At Altimetrik, Megan is responsible for expanding client relationships and developing new business opportunities in the US Central region. Her focus is on digital business and utilizing her experience to create high growth opportunities for clients. Moreover, she leads the company’s efforts in cultivating and enhancing our partnership with Salesforce, strategically positioning our business to capitalize on new business opportunities.

Prior to Altimetrik, Megan spent 10 years leading Customer Success at Salesforce, helping customers maximize the value of their investments across their technology stack. Prior to Salesforce, Megan spent over 15 years with Accenture, leading large transformational projects for enterprise customers.

Megan earned a Bachelor of Science in Mechanical Engineering from Marquette University. Beyond work, Megan enjoys playing sand volleyball, traveling, watching her kids soccer games, and is actively involved in a philanthropy (Advisory Council for Cradles to Crayons).

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes